Identifying biomarkers for detecting hidden cancer in patients with blood clots
Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
This study is trying to find new markers in the blood that can help spot hidden cancer in patients who have blood clots.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Danderyd Hospital Academic / other |
| Locations | 2 sites (Stockholm and 1 other locations) |
| Trial ID | NCT03781531 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify novel biomarkers that can help detect occult cancer in patients diagnosed with venous thromboembolism (VTE). It focuses on understanding the relationship between inflammation, hypercoagulability, and cancer, particularly through the study of neutrophil extracellular traps (NETs). By improving risk prediction models, the study seeks to determine which VTE patients may benefit from more extensive cancer screening. The research is conducted at Danderyd Hospital and Södersjukhuset in Stockholm.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with venous thromboembolism.
Not a fit: Patients who are more than two days post-diagnosis of VTE or cannot provide blood samples at baseline may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of cancer in patients with venous thromboembolism, potentially improving treatment outcomes.
How similar studies have performed: While there have been studies exploring biomarkers in cancer diagnostics, this specific approach focusing on VTE patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography; * \> 18 years or older; * Written informed consent Exclusion Criteria: * \> 2 days after VTE diagnosis; * No blood withdrawal at baseline
Where this trial is running
Stockholm and 1 other locations
- Danderyd Hospital — Stockholm, Sweden (Recruiting)
- Södersjukhuset — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Charlotte Thålin, M.D., Ph.D. — Karolinska Institutet
- Study coordinator: Charlotte Thålin, M.D., Ph.D.
- Email: charlotte.thalin@sll.se
- Phone: +46709565120
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.